Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ...

A one-time injection of Lumevoq demonstrated sustained visual acuity improvements with a favorable safety profile at 5 years ...

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF ...

Martin Friedlander, MD, PhD, discusses phase 3 macular telangiectasia findings, highlighting the potential for a decade-long ...

The Food and Drug Administration (FDA) has expanded the labeling for Izervay™ (avacincaptad pegol intravitreal solution) to include longer-term ...

Multiple subcutaneous doses safe and well-tolerated >69% reduction in anti-VEGF intravitreal (IVT) treatment burden in study eyes >67% ...

The updated label allows physicians to prescribe Izervay without a limitation on duration for patients with geographic ...

including intravitreal injections of anti-VEGF drugs. The current status of these novel therapeutic agents is also discussed. The slit-lamp binocular macular biomicroscopy demonstrates that CNV ...

Outlook Therapeutics' Lytenava has become the first ophthalmic formulation of VEGF inhibitor bevacizumab to be cleared for use by the NHS in England and Wales for treating wet age-related macular ...

When giving gluteal injections, it is safest to use the upper outer quadrant. The choice of site for injection must be based on good clinical judgment, using the best evidence available and ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

At least one of these had to include Avastin (bevacizumab). ELAHERE demonstrated an ORR by investigator of 31.7%, including five complete responses (CRs) The median DOR by investigator was 6.9 months.